GI Innovation transfers technology to Japan for allergy treatment drug for 298 billion won = South Korean report

On the 16th, South Korean pharmaceutical company GI Innovation transferred technology for the allergy treatment drug "GI-301" to Japanese peer Maruho for approximately 298 billion won (approximately 32,920,770,000 yen).
It was announced that. Under this agreement, GI Innovation will receive from Maruho an upfront contract fee that does not have to be returned, as well as stage-based remuneration such as clinical development, commercialization, and sales royalties, to advance the business.
I'm going to go. Maruho will conduct clinical trials and commercialize GI-301 in Japan. Jang Myung-ho, general manager of clinical strategy at GI Innovation, said, ``The demand for allergy drugs is increasing.
Many Japanese pharmaceutical companies have shown strong interest in GI-301 due to Japan's high demand for pharmaceutical products. Among them, Maruho is a leader in clinical trials and commercialization in the field of skin-related diseases.
We have decided to transfer the technology to The clinical trial in Japan through this technology transfer will be carried out on ``G-301'' by Yuhan Yoko, a major pharmaceutical company that holds the worldwide sales rights for GI-301.
It is also expected to support technology transfer. This is because clinical trials in Japan, which has a high proportion of allergic patients, are essential for pharmaceutical companies around the world.
Prior to this, in 2020, the company granted Yuhan Yoko the sales rights for GI-301 worldwide, excluding Japan, for approximately 1.4 trillion yen.
It was relocated for 000 million won (approximately 154,565,670,000 yen). GI-301 is currently undergoing Phase 1b of clinical trials in South Korea.